Acute myeloid leukemia (AML) is a tough nut to crack. It's the leukemic stem cells (LSC) that often cause relapses, making them a prime target for research. One approach gaining attention is radioimmunotherapy. This method uses radioactive isotopes to deliver a punch to these cells. The idea is simple: ionizing radiation (IR) can kill LSC, even if they lack specific ...
Cytotoxic T lymphocytes (CTLs) are crucial for fighting cancer, but many people with liver cancer (HCC) who have lots of these cells still face early relapse or resistance to treatments. Scientists don't fully understand why this happens. They studied 20 patients with liver cancer and CTLs to figure out what's going on. They used special stains to look at single cell...
Immunotherapy has been making waves in the treatment of esophageal cancer, especially when used after initial chemoradiation. But what about patients with esophageal squamous cell carcinoma who've had a different combo—immunochemotherapy before surgery? Does adjuvant immunotherapy (AIT) still matter for them? That's the question researchers are trying to answer. Ima...
Ever wondered how cancer cells trick the immune system into turning a blind eye? Well, there's an enzyme called Deltex E3 ubiquitin ligase 2, or DTX2, that does just that in liver cancer. Scientists found out that this enzyme helps cancer cells in the liver attract certain immune cells called neutrophils, which then act as shields for the cancer cells. These neutroph...
Immunotherapy, teamed up with chemotherapy, is giving a big boost to people with advanced, metastatic triple-negative breast cancer (TNBC). This combo helps keep the cancer from spreading for longer than chemotherapy alone. But who's getting the most benefits? That's a question scientists are still trying to figure out. Different groups of TNBC patients might be seei...
Let's talk about a powerful duo in the fight against advanced kidney cancer. Nivolumab and ipilimumab, often called NIVO + IPI, are like the dynamic duo of immunotherapy. They're used to treat people with intermediate- or high-risk advanced or metastatic renal cell carcinoma (mRCC). Now, you might be wondering, how well do they work in the real world, beyond the firs...
Scientists have been studying something called circulating tumor DNA, or ctDNA. These are tiny bits of DNA that cancer cells release into the bloodstream. They've found that checking these bits can help doctors know if a treatment is working. Researchers looked at patients with two types of kidney cancer: clear cell and non-clear cell. They were treated with either i...
Over the past few years, tiny nanoparticles made from special polymers have caught the eye of researchers and doctors for treating cancer. These smart particles can deliver medicine right where it's needed in the body. However, while many amazing ideas have come up in labs, not many have made it to real patient treatments. This is because of worries about safety, how...
Allergies have become quite common these days. Doctors think this is because of a mix of our genes, how we live, and what's in our environment. One important way to treat allergies is called Allergen-Specific Immunotherapy, or AIT for short. This method can actually change how your body deals with allergies over time. Scientists have learned a lot about how allergies...
Scientists are exploring whether certain immunity signals in the body, known as biomarkers, can forecast the comeback of esophageal squamous cell carcinoma (ESCC) within three years. This type of cancer often returns after patients undergo a mix of treatments including immunotherapy and chemotherapy before surgery. The goal is to pinpoint these biomarkers to better u...